Recent Postings to generic-tadalafil.info

E-Alerts

Worst Pills, Best Pills Newsletter Articles

  View the entire December 2018 issue in PDF format

  View the entire November 2018 issue in PDF format

  View the entire October 2018 issue in PDF format

  • False-Hope Alzheimer’s Disease Drugs
    (October 2018)
    The FDA has approved four drugs for treating Alzheimer’s disease, a devastating brain disorder that affects nearly 6 million Americans, most of whom are elderly. Learn why we have designated each of these drugs as Do Not Use.
  • New Research Shows Drugs Associated with a Risk of Depression Are Widely Used
    (October 2018)
    In this article, we summarize the results of a recent research study showing that use of medications that have depression as a potential adverse effect is very common. We also identify some of the many prescription medications that can cause depression symptoms, including suicidal thoughts or behavior.
  • Review of Lamotrigine (LAMICTAL)
    (October 2018)
    For certain types of epilepsy, lamotrigine is an appropriate treatment for preventing seizures. Learn about the common and serious adverse effects that can occur while taking this drug and how to take this drug safely.
  • FDA Announces Recalls of Certain Valsartan-Containing Medications Because of Cancer-Causing Contaminant
    (October 2018)
    We have received numerous questions from readers asking what to do about the recent recalls of valsartan-containing drugs sold by certain companies that were found to be tainted with a probable carcinogen. In this article, we offer advice for those patients who have been taking valsartan.
  • Question & Answer
    (October 2018)
    Several readers have asked us whether the FDA’s recent approval of a drug that reverses the anticoagulant effect of apixaban (ELIQUIS) and rivaroxaban (XARELTO) alters our classification of these two drugs as Do Not Use. Read our answer.
  • HHS Inspector General Documents Big Pharma’s Price Gouging of Seniors
    (October 2018)
    In his editor’s column, Dr. Michael Carome discusses the implications of a recent government report which found that annual out-of-pocket expenses for brand-name drugs covered under Medicare Part D have skyrocketed in recent years.

Additional Information from Public Citizen

  • (December 3, 2018)
    The Food and Drug Administration (FDA) is recklessly and needlessly endangering people by approving a super-strong opioid, Public Citizen and the head of a key FDA advisory committee said today. The FDA gave the green light for the medication, which is called sufentanil sublingual tablet (brand name Dsuvia) and is to be used to treat moderate-to-severe acute pain in a medically supervised setting. It is five to 10 times more potent than fentanyl and 1,000 times more potent than morphine.
  • (December 3, 2018)
    Public Citizen sent a letter to Dr. Carlos M. Garcia, the Director of Medicine at Utopia Wellness, informing him that Public Citizen had submitted complaint letters to the Federal Trade Commission, Food and Drug Administration, and Florida Board of Medicine regarding his medical center’s dissemination of false and misleading advertisements that promote the use of cesium chloride.
  • (December 3, 2018)
    Public Citizen sent a letter to the Florida Attorney General requesting an investigation of the use of falsified scientific citations in the advertisement and promotion of an illegal heart-toxic drug for treatment of cancer by Utopia Wellness, a Florida-based medical center. The medical’s website materials misleadingly claim that cesium chloride is safe and effective for treating cancer but offers no evidence from well-controlled clinical tests to support its claims.
  • (December 3, 2018)
    In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee, Public Citizen urged the committee to recommend that the FDA reject new drug application submitted by SpecGx for an immediate-release oral tablet formulation of oxycodone that is intended to be abuse-deterrent for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are
  • (December 3, 2018)
    In a joint op-ed, Dr. Sidney Wolfe, founder and senior adviser of Public Citizen’s Health Research Group, and Dr. Raeford Brown, chair of the Food and Drug Administration’s (FDA’s) Anesthetic and Analgesic Drug Products Advisory Committee, are highly critical of the FDA’s reckless decision to approve sufentanil sublingual tablets, a new opioid that will be sold under the brand name Dsuvia.